Updated interim data remain consistent, showing 10.3-month median PFS overall and 11.0-month median PFS in 2L patients with PI3Kα-mutated, HR+/HER2- metastatic breast cancer Data continue to support planned initiation of pivotal study in mid-2025 Next-generation triplet combinations with atirmociclib (CDK4-selective) & ribociclib ongoing CAMBRIDGE, Mass., June 02, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery pro ...

CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in two upcoming fireside chats in June: Jefferies Global Healthcare Conference on Wednesday, June 4, 2025 at 8:45 a.m. ETGoldman Sachs Global Healthcare Conference on Wednesday, June 11, 2025 at 2:40 p.m. ET The fire ...

Summary of Relay Therapeutics (RLAY) FY Conference Call - May 27, 2025 Company Overview - **Company**: Relay Therapeutics (RLAY) - **Event**: Sixth Annual Oncology Innovation Summit - **Key Speakers**: Sajeev Patel (President and CEO), Don Bergstrom (President of R&D), Peter Romer (Chief Commercial Development Officer) Key Industry Insights - **Focus Area**: Oncology, specifically targeting hormone receptor positive, HER2 negative breast cancer with PI3K alpha mutations - **Market Size**: Approximately 40% of patients with hormone receptor positive, HER2 negative breast cancer have a PI3K alpha mutation, indicating a significant patient segment that is poorly treated [7][8] Core Data and Efficacy - **Drug in Focus**: RLY2608, a selective PI3K alpha inhibitor - **Clinical Data**: - Previous data showed a median progression-free survival (PFS) of 9.2 months with RLY2608 compared to 5.5 months for the control (TruCap) [4][5] - Objective response rate (ORR) for RLY2608 was 39%, with 67% in kinase mutant patients [5][10] - Upcoming ASCO presentation expected to show over a year of follow-up data, aiming to confirm the durability and consistency of these results [6][50] Clinical Trial Insights - **Phase III Trial**: Focused on CDK4 experienced patients, with a randomized design of 540 patients comparing RLY2608 to capivasertib [41][42] - **Patient Population**: Primarily second-line patients, with potential inclusion of first-line patients who have received adjuvant CDK4 inhibitors [17][29] - **Exclusion Criteria**: Patients with prior PI3K pathway inhibitors will be excluded from the trial [48] Competitive Landscape - **Current Treatments**: Previous generation non-selective PI3K inhibitors have shown limited efficacy, with PFS typically between 5.5 to 7.5 months [8] - **Market Dynamics**: The approval of Roche's triplet therapy presents competition, but RLY2608's data suggests a strong position in the market [28] Financial Position - **Cash Position**: As of Q1 2025, the company reported a cash position of $710 million, sufficient to fund the phase III trial and other ongoing studies through 2029 [85][86] - **Partnership Considerations**: The company is open to partnerships, especially given current capital market conditions [87][88] Additional Considerations - **Vascular Malformations**: The company is also exploring RLY2608 for vascular malformations, with an estimated 170,000 patients in the U.S. having PIK3CA-related conditions, of which 5,000 to 15,000 are within the PROS population [64][65] - **Regulatory Landscape**: The failure of a confirmatory study for a competing drug (Alpalocep) leaves Relay Therapeutics in a favorable position as there are currently no fully approved agents for vascular malformations [66] Conclusion - The upcoming ASCO presentation is critical for Relay Therapeutics to validate its clinical data and establish its competitive edge in the oncology market, particularly for patients with PI3K alpha mutations in breast cancer. The company is well-positioned financially and strategically to advance its clinical programs and explore potential partnerships.

Relay Therapeutics, Inc. (RLAY) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change.The Zacks rating relies solely on a company's changing earnings picture. It tracks EPS estimates for the current and following years from the sell-side analysts covering the stock through a consensus measure -- the Zacks Consensus Estimate.Individual investors ...

Summary of Relay Therapeutics Conference Call Company Overview - **Company**: Relay Therapeutics (Ticker: RLAY) - **Event**: BofA Annual Healthcare Conference - **Date**: May 14, 2025 Key Industry Insights - **Focus on Precision Oncology**: The company has faced challenges in precision oncology and is now prioritizing its PI3K program for breast cancer, indicating a strategic shift in resource allocation towards this program [2][4] - **Restructuring and Cost Management**: Relay Therapeutics has made significant reductions in its research footprint due to limited access to capital, focusing on maximizing value from its balance sheet over the next three to five years [4][5] Financial Position - **Cash Reserves**: The company currently holds $710 million in cash, which is expected to sustain operations and support studies through 2029 [5] Clinical Development - **PI3K Alpha Program**: The PI3K alpha immune selective molecule (02/1400) is identified as a key driver for the company, with plans to advance through pivotal studies [5][9] - **Upcoming Studies**: The company is preparing for the Rediscover II Phase III study, with expectations of presenting updated data at the upcoming ASCO conference [9][10] - **Vascular Malformation Study**: A new study has been initiated for a PIK3CA mutant-driven genetic disease, with an estimated 170,000 patients in the U.S. [6][53] Competitive Landscape - **Benchmarking Against Competitors**: The company is comparing its clinical data against competitors, noting that its median progression-free survival (PFS) is significantly better than the competitive benchmark of 5.5 months [12][14] - **Differentiation Strategy**: Relay Therapeutics aims to establish a next-generation profile compared to existing therapies, emphasizing the importance of being first to market in a large patient population [19][20] Regulatory Considerations - **Potential Labeling Strategies**: The company is considering the evolving landscape of CDK4/6 therapies and aims to construct studies that could lead to line-agnostic approvals [21][23] Market Opportunity - **Vascular Malformations Market**: The potential market for PIK3CA-driven vascular malformations is significant, with estimates suggesting that 10-40% of patients may seek systemic therapy, translating to a meaningful commercial opportunity [53][54] Future Directions - **Ongoing Research**: The company plans to advance its Fabry and NRAS programs to IND readiness, with decisions on further development contingent on the macro environment and business considerations [57] Additional Notes - **Safety and Efficacy**: The company believes that its experience in oncology has de-risked safety profiles for its new indications, allowing for a more favorable assessment of efficacy in younger patient populations [43][44] - **Strategic Focus**: Relay Therapeutics is maintaining a small research footprint focused on high-value oncology targets while exploring additional preclinical programs as opportunities arise [57]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39385 RELAY THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Delaware 47-3923475 (State or other jurisdi ...

Exhibit 99.1 Relay Therapeutics Reports First Quarter 2025 Financial Results and Corporate Updates Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through clinical proof-of-concept data in Vascular Malformations Approximately $710 million in cash, cash equivalents and investments ...

Cash runway extended into 2029 Initiation of Phase 3 ReDiscover-2 trial on track for mid-2025 Initiated Phase 1 RLY-2608 vascular malformations clinical trial in Q1 Extended cash runway expected to fully fund the Company meaningfully past topline data for ReDiscover-2 trial and through clinical proof-of-concept data in Vascular Malformations Approximately $710 million in cash, cash equivalents and investments at end of Q1 2025 CAMBRIDGE, Mass., May 05, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nas ...

CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will report first quarter 2025 financial results and corporate highlights after the U.S. financial markets close on Monday, May 5, 2025. About Relay Therapeutics Relay Therapeutics (Nasdaq: RLAY) is a clinical-stage precision medicine company transforming the dru ...

Group 1 - The core point of the article is the upheaval in Relay Therapeutics' pipeline, particularly the outlicensing of the FGFR2 inhibitor lirafugratinib to Elevar [1] - The author emphasizes the importance of understanding the science behind biotech investments and aims to educate investors to avoid pitfalls in this sector [1] Group 2 - The article does not provide any specific financial data or performance metrics related to Relay Therapeutics or the broader biotech industry [1]